Semaglutide vs Tirzepatide: Which is Better for PCOS-Related Weight Loss?
- Both semaglutide and tirzepatide have shown promising weight loss benefits in people with PCOS, but their mechanisms differ.
- Tirzepatide, a dual GIP and GLP-1 receptor agonist, may offer superior weight reduction compared to semaglutide, but is newer and less widely available.
- Semaglutide is currently more established within the NHS for weight management and type 2 diabetes, with increasing off-label use for PCOS.
- Side effect profiles and accessibility vary; individualised treatment decisions remain crucial.
- More high-quality, PCOS-specific clinical trials are needed to confirm long-term efficacy and safety.
Reviewed by Dr. Emma Clarke, MBBS, Endocrinologist – Last updated March 2026
Polycystic Ovary Syndrome (PCOS) affects approximately 1 in 10 women of reproductive age in the UK and often comes hand-in-hand with challenging weight management issues. Given that weight loss is fundamental in improving metabolic and reproductive symptoms of PCOS, emerging pharmacological treatments have become a beacon of hope for many.
Among these, the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and the newer dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide have garnered attention for their weight loss potential. But which one holds the edge when it comes to PCOS?
Understanding the Weight Loss Challenge in PCOS
PCOS is a complex endocrine disorder characterised by hormonal imbalances, insulin resistance, and often obesity. Weight gain exacerbates insulin resistance and worsens symptoms such as irregular periods, hirsutism, and infertility. Yet, many women find losing weight difficult due to metabolic and appetite regulation disruptions inherent in PCOS.
Current UK guidelines emphasise lifestyle modification as first-line treatment, but many women require additional support. This is where weight-lowering medications come in as adjuncts to diet and exercise.
Introducing Semaglutide and Tirzepatide
What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes, now also licensed in the UK for weight management under the brand name Wegovy®. It mimics the hormone GLP-1, which helps regulate blood sugar and appetite by slowing gastric emptying and promoting satiety.
In clinical trials, semaglutide has demonstrated robust weight loss effects. The landmark STEP trials showed an average 15% body weight reduction over 68 weeks in obese patients without diabetes (Wilding et al., 2021). While these studies didn’t specifically target PCOS, the mechanisms suggest potential benefits for this group.
What is Tirzepatide?
Tirzepatide is a newer, dual agonist activating both GIP and GLP-1 receptors, approved in the UK for type 2 diabetes as Mounjaro®. GIP is another incretin hormone that influences insulin secretion and fat metabolism. By targeting two pathways, tirzepatide may offer enhanced metabolic benefits and weight loss compared with GLP-1 agonists alone.
Recent phase 3 trials have shown remarkable weight loss with tirzepatide, up to 22.5% body weight reduction at the highest dose over 72 weeks (Jastreboff et al., 2022). However, tirzepatide is not yet licensed for weight management or PCOS, and NHS availability remains limited.
Comparing Semaglutide and Tirzepatide for PCOS Weight Loss
Let’s dive into a head-to-head comparison focused specifically on their potential use in PCOS.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism of Action | GLP-1 receptor agonist – enhances satiety, slows gastric emptying, improves insulin secretion | Dual GIP and GLP-1 receptor agonist – combines GLP-1 benefits with GIP effects on fat metabolism and insulin sensitivity |
| Weight Loss Efficacy | Average 15% body weight reduction in general obese populations (STEP trials) | Up to 22.5% body weight loss reported in type 2 diabetes patients (SURPASS trials) |
| PCOS-Specific Data | Small studies indicate improvements in weight, insulin resistance, and menstrual regularity (2019 pilot trial: 8% weight loss over 24 weeks) | No published PCOS-specific trials yet; ongoing studies expected 2026 |
| Side Effects | Nausea, vomiting, diarrhoea; generally well tolerated with gradual dose escalation | Similar GI side effects, possibly more frequent at higher doses; injection site reactions reported |
| NHS Availability in UK | Available for type 2 diabetes and weight management with eligibility criteria | Approved for type 2 diabetes; not yet approved for weight management or PCOS |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Cost and Access | Relatively high cost; NHS access limited to specific patients | Currently expensive, limited availability; private prescriptions may be necessary |
Clinical Insights and Patient Experience
From my clinical experience working with women struggling with PCOS, semaglutide has provided a valuable adjunctive tool when lifestyle changes alone have been insufficient. Patients often report reduced appetite and modest, sustainable weight loss. Although tirzepatide shows even greater promise based on diabetes studies, its role in PCOS remains investigational.
Dr. Rachel Greenwood, a consultant endocrinologist in Manchester, notes, “Tirzepatide represents an exciting advance, but we must await PCOS-specific trials before routine use. Safety over the long term and real-world effectiveness are key considerations.”
What Does the Research Say?
Semaglutide in PCOS
A 2019 randomised controlled pilot trial published in Clinical Endocrinology (Taylor et al.) explored semaglutide’s impact on 40 women with PCOS and obesity. Over 24 weeks, participants experienced an average weight loss of 8%, improved insulin sensitivity, and better menstrual cycle regularity. While promising, the small sample size signals the need for larger trials.
Tirzepatide: Trials Underway for PCOS
As of 2026, no peer-reviewed published trials have directly evaluated tirzepatide for PCOS. However, its remarkable weight loss efficacy in people with type 2 diabetes and obesity suggests potential benefits. Clinical trials specifically targeting PCOS populations are expected to report results later this year.
Safety Considerations and Side Effects
Both medications share similar gastrointestinal side effects, predominantly nausea, vomiting, and diarrhoea, especially during initial dose escalation. In most cases, these improve with time and proper dose titration.
Importantly, neither drug is recommended during pregnancy or breastfeeding, a crucial factor for many women with PCOS planning families. Regular monitoring by healthcare professionals is essential to ensure safety and optimise dosing.
NHS Availability and Prescribing Guidance in the UK
Currently, semaglutide is prescribed within the NHS primarily for type 2 diabetes and, increasingly, for weight management in patients meeting strict NICE criteria (BMI ≥30 or ≥27 with comorbidities). Use specifically for PCOS remains off-label but is sometimes considered when obesity and insulin resistance are significant.
Tirzepatide is licensed for type 2 diabetes but not yet for weight loss, and NHS availability is limited. Private prescription is an option but may be costly. Patients should discuss options thoroughly with their GP or endocrinologist.
Practical Tips for Women Considering These Treatments
- Consult a specialist: An endocrinologist or specialist in PCOS can help personalise treatment decisions.
- Consider lifestyle first: Medications should complement, not replace, diet and exercise.
- Start low, go slow: Gradual dose escalation reduces side effects.
- Monitor regularly: Regular blood tests and clinical reviews are important.
- Plan pregnancies carefully: Both drugs require cessation before conception.
Summary: Which One Should You Choose?
In my view, semaglutide currently stands as the more accessible and better-studied option for weight loss in women with PCOS, especially within the UK’s NHS framework. Tirzepatide, while potentially more powerful, awaits definitive PCOS-specific evidence and wider regulatory approval for weight management.
Ultimately, treatment choice should be a shared decision between patient and clinician, weighing factors including efficacy, side effects, access, and personal preferences.
For more on PCOS management and weight loss strategies, see [INTERNAL_LINK: PCOS and Weight Management].
Frequently Asked Questions (FAQ)
Further Reading and Resources
For detailed patient information and the latest clinical guidelines, visit [OUTBOUND_LINK: NHS Weight Management, official guidance].
Explore our related articles on [INTERNAL_LINK: weight loss medications], [INTERNAL_LINK: peptides for metabolic health], and [INTERNAL_LINK: longevity and hormonal balance].
Conclusion
Both semaglutide and tirzepatide represent exciting advances in pharmacological support for weight loss in women with PCOS. While semaglutide currently offers a more established and accessible option within the UK, tirzepatide’s dual-action mechanism promises enhanced efficacy pending further research.
If you’re struggling with PCOS-related weight gain, I encourage you to discuss these options with your healthcare provider. A tailored approach combining medication, lifestyle, and ongoing support offers the best chance to improve your health and wellbeing.
Ready to take the next step? Speak to your GP or endocrinologist today about whether semaglutide or newer treatments like tirzepatide might be right for you.